Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness

Atherosclerosis
S SivapalaratnamE de Groot

Abstract

We investigated the effectiveness of statins in daily practice in reducing the arterial wall thicknesses by comparing the carotid intima-media thickness (cIMT) between statin-treated familial hypercholesterolemia (FH) patients and their unaffected spouses. FH subjects treated with LDL-c lowering medication for at least 5 years and their unaffected spouses were included in this observational study. Clinical data and carotid intima-media thickness (cIMT) as surrogate marker for atherosclerosis were acquired. In total 40 FH patients, age 48.4±4.2 years, and their 40 unaffected spouses, age 47.4±3.9 years, were included. Pre-treatment total cholesterol levels of FH patients were on average 9.3±2.0 mmol/L. Treated FH patients and unaffected spouses exhibited similar LDL-c (3.8±1.5 vs. 3.5±1.1 mmol/L; p=0.25) and total cholesterol levels (5.8±1.6 vs. 5.6±1.1 mmol/L; p=0.56). Also, in a multivariate model cIMT adjusted for age and sex did not differ between affected and spouses (95% CI: -0.032 to 0.092 mm; p=0.34). Long-term statin treatment normalizes cIMT in severe FH patients and therefore it is likely that the extreme risk of cardiovascular disease in FH patients is significantly reduced by this therapy.

References

Jun 17, 2004·Circulation·Eric de GrootJohn J P Kastelein
Jul 11, 2006·European Heart Journal·Emily S van Aalst-CohenJohn J P Kastelein
Apr 27, 2007·The New England Journal of Medicine·Robert A Hegele
Apr 12, 2008·Expert Review of Cardiovascular Therapy·Roeland HuijgenBarbara A Hutten
Aug 2, 2008·The New England Journal of Medicine·Daniel Steinberg
Nov 13, 2008·BMJ : British Medical Journal·Jorie VersmissenEric J G Sijbrands

❮ Previous
Next ❯

Citations

Sep 29, 2011·International Journal of Clinical Practice·A S Wierzbicki
Aug 22, 2012·Annals of Nutrition & Metabolism·Erine A Kupetsky-Rincon, Jouni Uitto
Dec 8, 2015·Expert Review of Cardiovascular Therapy·Neil J StoneSakina Kazmi
Jan 17, 2016·Atherosclerosis·Michael H DavidsonAndrew M Tershakovec
May 27, 2011·Journal of Clinical Lipidology·Jennifer G RobinsonUNKNOWN National Lipid Association Expert Panel on Familial Hypercholesterolemia
Mar 31, 2015·International Journal of Clinical Practice·A Viljoen, A S Wierzbicki
Dec 18, 2013·Clinical and Translational Science·Erine A KupetskyJouni Uitto
Dec 18, 2018·Journal of Epidemiology·Katsuyasu KoudaToshimasa Nishiyama
Jun 13, 2012·Clinical and Translational Science·Erine A Kupetsky-RinconJouni Uitto
Mar 9, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Chang LiuYun Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.